Christopher J. Hoimes
Oncology | Internal Medicine
20 Duke Medicine Cir
Clinic 5 Cancer Center
Durham, NC 27710
Clinic 5 Cancer Center
Durham, NC 27710
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Journal: The New England journal of medicine
Published: July 22, 2026
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.
Journal: Research square
Published: July 10, 2026
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: March 09, 2026
Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
Journal: Urologic oncology
Published: December 02, 2025
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.
Journal: Clinical genitourinary cancer
Published: December 02, 2025
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
Journal: ESMO open
Published: November 06, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal: The oncologist
Published: June 09, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Journal: European urology
Published: May 07, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.
Journal: JAAD case reports
Published: March 27, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Journal: The oncologist
Published: February 04, 2025
Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors.
Journal: Current problems in diagnostic radiology
Published: October 04, 2024
Last Updated: 09/26/2026